Bolt Biotherapeutics, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023; balance-sheet comparisons are with December 31, 2022. Bolt is a clinical-stage cancer immunotherapy company. It has no product-sales revenue; reported revenue is from collaborations. Financial figures below are in millions of dollars unless stated otherwise.
Financial results and liquidity
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| Collaboration revenue | $1.826 | $0.813 |
| Research and development expense | $14.625 | $18.385 |
| General and administrative expense | $5.616 | $6.304 |
| Operating loss | $18.415 | $23.876 |
| Interest income, net | $1.435 | $0.198 |
| Net loss | $16.980 | $23.678 |
| Net loss per share, basic and diluted | $0.45 | $0.64 |
| Operating cash used | $23.399 | $24.314 |
- Cash and cash equivalents were $14.836; marketable securities totaled $156.129, for combined cash and investments of approximately $171.0. Restricted cash was $1.565.
- Current assets were $131.609 and current liabilities $16.253. Total liabilities were $48.495, including $22.052 of operating lease liabilities. The filing reports no outstanding debt.
- Accumulated deficit was $312.068; stockholders’ equity was $157.686. Collaboration revenue is not a product-sales margin measure; the filing does not provide a meaningful gross margin.
Changes versus prior comparable period
- Revenue increased $1.013 million, principally from continued services under the Genmab and Innovent collaborations.
- R&D expense fell $3.760 million, mainly from lower manufacturing costs and research and development contract services, partly offset by higher clinical-trial patient costs.
- G&A expense decreased $0.688 million, primarily due to lower consulting and professional-services costs.
- Net loss narrowed by $6.698 million. Higher interest income and lower operating expenses contributed; operating cash use decreased by $0.915 million.
- Cash and short-term investments declined from $168.888 million at year-end to $126.379 million, while long-term investments increased from $23.943 million to $44.586 million, reflecting the investment portfolio’s maturity profile and activity.
Outlook, programs and risks
- Management said existing cash, cash equivalents and marketable securities should fund operations for at least 12 months following the May 11, 2023 filing date. Near-term spending is expected to support key milestones for BDC-1001 and BDC-3042, clinical trials, manufacturing, R&D and personnel. The company expects continuing losses and says funding needs may rise as programs advance.
- BDC-1001 completed Phase 1 and has a recommended Phase 2 dose. The company described planned Phase 2 evaluation in HER2-positive solid tumors, including studies involving nivolumab and pertuzumab; it expected the pertuzumab study to begin in 2023. BDC-3042 is a Dectin-2 agonist antibody program.
- Potential Genmab and Innovent milestone and royalty payments are contingent on future development and commercial outcomes and were excluded from current collaboration transaction prices because their timing and probability could not be estimated.
- Key risks include clinical and regulatory uncertainty, need for future capital, possible dilution or unfavorable financing terms, reliance on single-source suppliers, and macroeconomic, inflation, interest-rate, geopolitical and supply-chain disruptions. Management noted that risk factors had not materially changed from the 2022 Form 10-K.
- Available-for-sale investments had $0.326 million in unrealized losses at quarter-end, attributed primarily to interest-rate changes; the company recorded no credit-loss allowance or investment impairment. A Stanford license agreement was terminated effective May 10, 2023, after quarter-end, with no payment due. Potential supply-agreement milestone payments were up to $2.0 million.
- Management reported disclosure controls and procedures were effective at a reasonable assurance level and no material change in internal control over financial reporting during the quarter. No material legal proceedings were reported.
Important facts for investors to verify
- Whether clinical-trial progress, enrollment, costs and timelines for BDC-1001 and BDC-3042 support management’s stated plans.
- Whether the approximately $171.0 million of cash and investments remains sufficient as trial and manufacturing expenses evolve; the runway estimate is forward-looking.
- How collaboration work, deferred revenue and any future opt-in, milestone or royalty rights develop with Toray, Genmab and Innovent.
- Whether supplier concentration, lease commitments and financing needs create material constraints or dilution risk.
- Whether post-quarter developments, including the Stanford license termination, have further financial or program implications.